Table 1.
Patients’ and treatment characteristics. BED10 = biologically effective dose (assuming an α/β ratio of 10); 3DCRT = 3-D conformal radiotherapy; 2DRT = 2-D radiotherapy; IMRT = intensity-modulated radiotherapy; VMAT = volumetric modulated arc therapy; Tomo = tomotherapy.
| Patients’ Characteristics (Per Access) | |||
|---|---|---|---|
| Lines of Systemic Treatment before (Number and Percentage, Data Available for 409 Accesses) | |||
| Mean 1.65 | Range 0–10 | ||
| One line 42 (10.3%) | |||
| Two lines 65 (15.9%) | |||
| Three lines 38 (9.3%) | |||
| Four lines 28 (6.8%) | |||
| Five or more lines 43 (10.5%) | |||
| Number of Treated Lesions | |||
| Mean 1.41 | Range 1–4 | ||
| One lesion 274 (66.7%) | |||
| Two lesions 110 (26.8%) | |||
| Three or more 27 (6.6%) | |||
| Age at Start of Radiotherapy | |||
| Median 68.1 years | Range 31.2–92.5 years | ||
| Treatment Characteristics (per Lesion) | |||
| Systemic Treatment Concurrent with Radiotherapy | |||
| No 220 (38.1%) | Chemotherapy 76 (13.2%) | Biologic treatment 281 (48.7%) | |
| Type of concurrent biological systemic treatment | |||
| Lenalidomide or lenamide-containing combinations 76 (13.2%) | |||
| Bortezomib 67 (11.6%) | |||
| Bortezomib-containing combinations 117 (20.3%) | |||
| Other biological agents 21 (3.6%) | |||
| Site of treated lesions | |||
| Vertebral 346 (60%) | Extremities 108 (18.7%) | Pelvic bones 57 (9.9%) | |
| Ribs/sternum 36 (6.4%) | Skull 15 (2.6%) | Other 15 (2.6%) | |
| Radiotherapy BED10 | |||
| Less than 15 Gy 42 (7.3%) | 15–38 Gy 165 (28.6%) | More than 38 Gy 370 (64.1%) | |
| Radiotherapy schedules | |||
| 30 Gy/10 fr 360 (62.4%) | 20 Gy/5 fr 158 (27.4%) | 8 Gy/1 fr 34 (5.9%) | |
| Radiotherapy technique | |||
| 3DCRT 440 (76.3%) | 2DRT 117 (20.3%) | IMRT/VMAT/Tomo 20 (3.5%) | |